UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarti…
| Métrica | UCB.BR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 71.5% | 57.4% | +14.1% |
| Operating Margin | 21.5% | -34.4% | +55.9% |
| Net Margin | 17.3% | -32.5% | +49.8% |
| FCF Margin | 16.4% | -12.6% | +29.0% |
| ROE | 10.6% | -39.2% | +49.8% |
| ROA | 6.1% | -30.9% | +37.1% |
| Current Ratio | 1.36 | 2.73 | -1.37 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 6.1% | — |
| ✓Flujo de caja operativo positivo | €1.2B | €761M |
| ✓Rentabilidad sobre activos al alza | 6.1% | 2.2% |
| ✓Caja operativa/activos supera al ROA | 7.2% | ROA 6.1% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 1.36 | 1.32 |
| ✓Sin aumentar el nº de acciones | 194M | 195M |
| ✓Margen bruto al alza | 71.5% | 67.5% |
| ✓Rotación de activos al alza | 0.35 | 0.34 |
| Calidad del negocio | FY24 |
|---|---|
| ✓Margen FCF > 10 % | 16.4% |
| ✗ROCE > 10 % | 9.6% |
| ✗Ventas > 5 %/año (3 años) | 2.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 32.8% |
U C B cotiza a 204.60 EUR y tiene una capitalización bursátil de €39.0B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud